


## Lagociclovir valactate

Cat. No.:	HY-107026
CAS No.:	1001670-19-4
Molecular Formula:	C <sub>19</sub> H <sub>27</sub> N <sub>6</sub> O <sub>6</sub>
Molecular Weight:	454.45
Target:	HBV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

Description	Lagociclovir valactate is a prodrug of Lagociclovir (HY-14844). Lagociclovir valactate is an orally active anti-HBV agent <sup>[1]</sup> .		
IC <sub>50</sub> & Target	HBV <sup>[1]</sup>		
In Vivo	Lagociclovir valactate (20 or 60 mg/kg; p.o.; daily for 10 weeks) shows anti-woodchuck hepatitis virus (WHV) activity in woodchucks <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	Woodchucks with chronic WHV infection <sup>[1]</sup>	
	Dosage:	20 or 60 mg/kg	
	Administration:	Oral, daily for 10 weeks	
	Result:	Reduced WHV viremia effectively and maintained WHV DNA at a very low level.	
	Animal Model:	Woodchucks <sup>[1]</sup>	
	Dosage:	10 or 40 mg/kg	
	Administration:	Oral (Pharmacokinetic Analysis)	
	Result:	Average pharmacokinetic parameters for Lagociclovir after oral administration of Lagociclovir valactate to healthy and chronically WHV infected woodchucks <sup>[1]</sup>	
	Pharmacokinetic parameter for Lagociclovir	Healthy woodchucks (n = 4) receiving Lagociclovir valactate at 10 mg/kg	Healthy woodchucks (n = 4) receiving Lagociclovir valactate at 40 mg/kg

WHV-infected woodchucks (n = 14) receiving Lagociclovir valactate at 60 mg/kg
---

